MR-Guided Adaptive Radiotherapy for Bladder Cancer

Radiotherapy has an important role in the curative and palliative treatment settings for bladder cancer. As a target for radiotherapy the bladder presents a number of technical challenges. These include poor tumor visualization and the variability in bladder size and position both between and during treatment delivery. Evidence favors the use of magnetic resonance imaging (MRI) as an important means of tumor visualization and local staging. The availability of hybrid systems incorporating both MRI scanning capabilities with the linear accelerator (MR-Linac) offers opportunity for in-room and real-time MRI scanning with ability of plan adaption at each fraction while the patient is on the treatment couch. This has a number of potential advantages for bladder cancer patients. In this article, we examine the technical challenges of bladder radiotherapy and explore how magnetic resonance (MR) guided radiotherapy (MRgRT) could be leveraged with the aim of improving bladder cancer patient outcomes. However, before routine clinical implementation robust evidence base to establish whether MRgRT translates into improved patient outcomes should be ascertained.

Download Full-text

Abstract B02: TP63 isoform expression landscape associations with bladder cancer patient outcomes

10.1158/1557-3265.bladder19-b02 ◽

2020 ◽

Author(s):

Armand Bankhead ◽

Thomas McMaster ◽

Phillip L. Palmbos

Keyword(s):

Bladder Cancer ◽

Cancer Patient ◽

Patient Outcomes ◽

Bladder Cancer Patient ◽

Isoform Expression

Download Full-text

The Validity of Magnetic Resonance Imaging (MRI) in the Staging of Bladder Cancer: Comparison with Computed Tomography (CT) and Transurethral Ultrasonography (US)

Japanese Journal of Clinical Oncology ◽

10.1093/oxfordjournals.jjco.a039240 ◽

1988 ◽

Keyword(s):

Magnetic Resonance Imaging ◽

Computed Tomography ◽

Bladder Cancer ◽

Magnetic Resonance ◽

Resonance Imaging ◽

Magnetic Resonance Imaging Mri

Download Full-text

Magnetic-resonance-guided Radiation Therapy With Simultaneous Integrated Boost at Mid-bladder Volume for Bladder Cancer

10.21203/rs.3.rs-751077/v1 ◽

2021 ◽

Author(s):

Janjira Petsuksiri ◽

Chanida Sathitwatthanawirot ◽

Utumporn Puangragsa ◽

Wisawa Phongprapun ◽

Pittaya Dankulchai ◽

...

Keyword(s):

Bladder Cancer ◽

Radiation Therapy ◽

Magnetic Resonance ◽

Cancer Patient ◽

Treatment Time ◽

Simultaneous Integrated Boost ◽

Bladder Volume ◽

Bladder Cancer Patient ◽

Tumor Bed ◽

Integrated Boost

Abstract Background and Purpose: To report the workflow and dose accumulation for bladder preservation for a bladder cancer patient, using magnetic-resonance-guided radiation therapy (MRgRT) and the simultaneous integrated boost (SIB) technique at mid-bladder volume.Materials and Methods: A muscle-invasive bladder cancer patient was treated with MRgRT. The patient was treated with the SIB technique at mid-bladder volume, with 45 Gy to the whole bladder (CTV WB) and 55 Gy to the tumor bed (CTV boost) in 20 fractions. Daily re-optimization with an adapt-to-position (ATP) strategy was utilized for dose adjustment to encompass the bladder within anisotropic planning target volume (PTV WB and PTV boost). Results: The mean daily treatment time was 55 minutes (range, 35–73). The actual whole-bladder and tumor-bed-boost doses were 45.74 ± 5.91 and 54.1 ± 4.62 Gy, respectively. PTV WB encompassing CTV WB was 95.69% ± 5.36%. PTV boost encompassing CTV boost was 97.52% ± 6.05%. The actual rectal and bowel doses were below the reference plan doses.Conclusions: The use of MRgRT with the SIB and ATP strategy proved feasible for bladder cancer treatment. Mid-bladder volume allowed treatment with the SIB technique under MR monitoring.

Download Full-text